Expanded access for treatment of hereditary angioedema attacks
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This program provides an experimental treatment called deucrictibant for people with hereditary angioedema (HAE) who have attacks that are not controlled by other approved medicines. It aims to see if this treatment can safely and effectively stop HAE attacks when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 75 years old.
- You must have a confirmed diagnosis of hereditary angioedema (HAE).
- If you have HAE with normal C1 inhibitor, you must have a documented genetic mutation related to HAE, or meet specific clinical criteria including that your attacks do not respond to high-dose antihistamines and you get relief from icatibant.
- You must have tried or cannot use other approved HAE treatments (like Berinert, Firazyr, or Kalbitor) because they did not work or caused problems.
- You must not be eligible for or able to join a clinical trial, and you must be residing in the US or US territories.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the program, and you must not have other significant health conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This trial tests an experimental medication called sebetralstat for treating angioedema attacks in children with hereditary angioedema (HAE). If your child is between 2 and 11 years old and has HAE, they may be able to join.
This trial tests if sebetralstat can prevent swelling attacks before medical procedures in people with HAE types I or II. You take the medicine short-term before your procedure to see if it helps protect you from an attack.
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
Hear when a new Hereditary Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.